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ABSTRACT
This study was aimed to develop the new transdermal formulation to improve the permeability of buprenorphine.  The apparent
partition coefficients of buprenorphine were measured using the buffers at pH 1.2 to 10.0 as aqueous phase.   The solubility of
buprenorphine was 12.97 μg/mL in the 0.1 M phosphate buffer at pH 6.8. The influences of vehicles at different pH, adhesives,
and permeation enhancers on the penetration of buprenorphine through nude mouse skin were investigated using the static Franz
diffusion cells.  The permeation parameter Jss of buprenorphine increased along with the reduction of the pH of receptor fluid, and
the vehicle at pH 6.8 was used in the following skin permeation studies. The pressure sensitive adhesives (PSA) including polyisobutylene (PIB), polystyrene-block-polyisoprene-block-polystyrene (SIS), and acrylic adhesives were evaluated. The permeability
of buprenorphine was higher in the PIB or SIS adhesives than that in the acrylic adhesives under the condition without enhancer.
When combined the enhancers with propylene glycol (PG) to improve the penetration of buprenorphine, the permeation-enhancing
effects of enhancers were in the following order: lauric acid > linolenic acid > menthol > oleic acid > N-methyl-2-pyrrolidone
(NMP) > laurocapram > glabridin. Finally, a matrix-type transdermal delivery system for buprenorphine was formulated using
acrylic adhesive, PG, and lauric acid. The Jss parameter was 2.68 ± 0.20 μg/cm 2/h and buprenorphine permeated across the nude
mouse skin was 31.68%.
Key words: buprenorphine, skin permeation, transdermal patch, adhesive, enhancer

INTRODUCTION
Buprenorphine is a partial agonist at the mu opioid
receptor and an antagonist at the kappa receptor in the
central nervous system (CNS) and peripheral tissues,
where it binds to both receptors with high affinity(1,2).
Effects on analgesia appear to occur as a result of mu
agonist activity(3).  Buprenorphine produces dose-related
analgesia and is 25-50 times more potent than an equivalent dose (by weight) of morphine (4).
Buprenorphine has been used to control cancer pain
via several routes. Parenteral and sublingual preparations
have been initially used (5).   For example, Buprenex® in
the US and Temgesic® in most European countries have
been widely prescribed for the treatment of moderate
to severe pain (6).   A transdermal matrix patch formulation of buprenorphine, Transtec®, has become available
in three dosage strengths: the patches contained 20, 30,
and 40 mg of buprenorphine and have been designed to
release buprenorphine at the controlled rate of 35, 52.5,
and 70 μg/h over a period of 72 hours, respectively, each
* Author for correspondence.  Tel: 0921-955-900;
E-mail: chen7755@gmail.com

corresponding to a daily dose of 0.8, 1.2, and 1.6 mg.  The
three dosage strengths are indicated for the treatment of
moderate to severe cancer pain and severe pain unresponsive to nonopioid analgesics (7).   Transtec® has a significant lag time (12-24 hours) to reach clinically effective
concentrations (0.1-0.5 ng/mL)(7,8).
The transdermal drug delivery system (TDDS)
would avoid the first-pass effect, reduce the side effects,
and control the release of drugs over long term.   The
pressure sensitive adhesives (PSA) used commonly in
the transdermal patch are polyisobutylene, polystyrene-block-polyisoprene-block-polystyrene, and acrylic
adhesive (9).   Because the physicochemical properties of
PSA could affect the penetration of a drug in PSA across
the skin, the selection of suitable PSA matrix would be
important in designing a transdermal patch(10,11).
The permeation enhancers are usually incorporated
in TDDS to improve the diffusion kinetics of the drug
administered and they can overcome the intrinsic resistance of the stratum corneum and enhance the permeation
rate of the active pharmaceutical ingredient (9).  However,
the structure-activity relationship between enhancers and
drugs are still indistinct.  It is accepted that the effect of
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enhancer is dependent on the physicochemical properties
of drugs and the combination with the excipients.  A variety of enhancers have been investigated to promote the
skin permeability of drugs in the literatures(9,12,13).
The purpose of this study was to develop the new
transdermal formulation to improve the permeability of
buprenorphine.  Because the intrinsic aqueous solubility
of neutral buprenorphine base was 12.7 ± 1.2 μg/mL at
23°C, buprenorphine base was practically insoluble (14).
The objectives of this study were firstly to determine the
lipophilicity and solubility of buprenorphine.  In order to
develop an optimal transdermal formulation, the effects
of vehicles at different pH, adhesives, and permeation
enhancers on the penetration of buprenorphine through
the nude mouse skin were also evaluated.

MATERIALS AND METHODS
I. Materials
Buprenorphine, 21-cyclopropyl-7α-[(S)-1-hydroxy1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine, was purchased from Tasmanian Alkaloid
and the purity was 99%.   The acrylic adhesives including Acryl-1 (NS-2287®), Acryl-2 (NS-100 ®), Acryl-3
(NS-200 ®), and Acryl-4 (NS-300 ®) were manufactured
by National Starch and Chemical Company. Polyisobutylene (PIB), polystyrene-block-polyisoprene-blockpolystyrene (SIS), propylene glycol (PG), mineral oil,
liquid paraffin, lauric acid, linolenic acid, oleic acid, and
menthol were obtained from Sigma-Aldrich.   Glabridin and laurocapram were offered by Shanghai Healthwell Chemical.  Rosin ester and N-methyl-2-pyrrolidone
(NMP) were purchased from Robert Kraemer GmbH and
Merck, respectively. The backing sheet SCOTCHPAK®
was obtained from 3 M.   All other chemicals were of
analytical grade.
II. Determination of Buprenorphine
The samples of buprenorphine in this study were
analyzed by HPLC (Hewlett-Acrylkard 1100) equipped
with a UV detector at 230 nm, and an XBridgeTM Shield
RP18 column (4.6 × 75 mm, 2.5 μm; Waters). The column
temperature was 30°C.   The mobile phase consisted of
acetonitrile / 0.063 M ammonium bicarbonate (pH 9.5)
(58:42, v/v) at the flow rate of 1.5 mL/min. The mobile
phase was degassed by an ultrasonic bath and filtered by
a Millipore vacuum filter system equipped with a 0.22
μm filter prior to use. The injection volume was 40 μL
for each analysis. This HPLC analytical system has been
validated (15).
III. Buprenorphine Lipophilicity Studies
The apparent partition coefficients (P) of buprenor-

phine were determined using n-octanol as organic phase
and 0.1 M phosphate buffers adjusted to pH 4.5, 6.8, or
7.4 as aqueous phase.   The pH 1.2 and 10.0 as aqueous
phase were also used by titrating with 1.0 M hydrochloric acid and 0.063 M ammonium bicarbonate, respectively. The apparent partition coefficient was determined
by adding 20 mg of buprenorphine to 20 mL of aqueous
phase and then mixing with 20 mL of n-octanol.   After
equilibrating for 24 hours in a water bath at 25°C, the
aqueous phase was separated by centrifugation (3,000
rpm for 15 min) and assayed for buprenorphine.   The
above processes were carried out for five times and the
partition coefficients were calculated (16,17).
IV. Buprenorphine Solubility Studies
The solubility of buprenorphine was determined in
0.1 M phosphate buffers at pH 5.0, 5.5, 6.0, 6.8, and 7.4.
Excess amount of buprenorphine were added to known
volumes of the phosphate buffers and equilibrated in a
water bath at 32°C under continuous stirring at 250 rpm
for 24 hours. The samples were filtered through the 0.22
μm filters individually and then analyzed as described.
This system was performed three times each(16).
V. Preparation of Buprenorphine Transdermal Patch
The PIB-1, PIB-2, SIS-1, Acryl-1, Acryl-2, Acryl3, or Acryl-4 adhesive solution in organic solvent was
mixed with buprenorphine in ethyl acetate with or without permeation enhancers according to the following
protocol. The PSA were prepared by coating the above
solutions on the polyester release liners, and set in the
oven at 50°C for 20 minutes to remove organic solvents.
The backing sheets were then placed on the dried adhesive films to make the transdermal patches (10,18,19).
VI. Buprenorphine in Vitro Permeation Studies
The skin permeation of buprenorphine was evaluated in vitro using the static Franz diffusion cells with
dilution area of 1 cm 2.   The receptor compartment was
filled with 8 mL phosphate buffer as the vehicle. The
nude mouse skin (Narl: ICR-Foxn1nu) was cut about 2 ×
2 cm 2 and then mounted on the cell and the transdermal
patch was applied to the skin.  The receptor compartment
was stirred at 32°C throughout the experiment. Samples
(6 mL) were withdrawn after 3, 6, 9, 21, 33, 45, 57, and
72 hours from the receptor compartment followed by
replacement with a fresh vehicle.   The samples withdrawn were filtered and analyzed by HPLC for the determination of buprenorphine permeated(20).
(I) Influence of Vehicles at Different pH
The Acryl-1 was used as the adhesive and the
concentration of buprenorphine was kept at 10% (w/w)
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in the formulation.   Five 0.1 M phosphate buffers were
adjusted to pH 5.0, 5.5, 6.0, 6.8, and 7.4 as the vehicles
which were used to evaluate the influence of pH on the
skin permeability of buprenorphine (21).
(II) Influence of Adhesives
The composition and trade name of seven PSA were
employed as follows: PIB-1 (PIB Mw 1.2 × 10 6: mineral oil: liquid paraffin: rosin ester = 3:1:1:5), PIB-2 (PIB
Mw 1.2 × 106: PIB Mw 2.0 × 105: mineral oil: rosin ester
= 1:2:1:5), SIS-1 (SIS: rosin ester: liquid paraffin = 4.5:
5.5:1), Acryl-1 (NS-2287®), Acryl-2 (NS-100 ®), Acryl-3
(NS-200 ®), and Acryl-4 (NS-300 ®). Each PSA was used
as the adhesive and the concentration of buprenorphine
was kept at 10% (w/w) in each formulation.  The vehicle
used in this study was 0.1 M phosphate buffer at pH 6.8.
(III) Influence of Permeation Enhancers
The permeation enhancers used in this study included lauric acid, linolenic acid, oleic acid, menthol, glabridin, laurocapram, and NMP. Acryl-1 was used as the
adhesive. The concentrations of buprenorphine, PG, and
each enhancer were kept at 10% (w/w) in each formulation.   The formulation of control test was of no any
enhancer.  The vehicle used in this study was 0.1 M phosphate buffer at pH 6.8(21,22).
(IV) Formulation Optimization
The skin permeation of buprenorphine was more
efficient in PIB-1, PIB-2, SIS-1, and Acryl-2 adhesives
than in other acrylic adhesives without any enhancer.  
Each of the four adhesives was combined with PG/lauric
acid or PG/linolenic acid in order to obtain the optimal
formulation. The concentrations of buprenorphine, PG,
lauric acid, or linolenic acid were kept at 10% (w/w) in
each formulation.  The vehicle used in this study was 0.1
M phosphate buffer at pH 6.8.
(V) Data Treatment
The amount of buprenorphine permeated through
the nude mouse skin during a sampling interval was
calculated based on the measured concentration and
volume of the receptor compartment.   Each experiment
was replicated at least three to six times.  The cumulative
amount of buprenorphine permeated per cm 2 of the skin
versus time was plotted.  The lag time (t L) and the steadystate flux (Jss, μg/cm 2/h) were determined from the intercept and the slope of the linear portion of the plot.  The
percentage of buprenorphine permeated was calculated
as the ratio of final cumulative amount of buprenorphine
permeated and the amount of buprenorphine loaded.  The
enhancement ratio (ER) was calculated as the ratio of Jss
values in the presence and absence of enhancer.  All data

were calculated and presented as mean ± SD (16,22-24).  ER
= Jss with enhancer / Jss without enhancer

RESULTS AND DISCUSSIOn
I. Lipophilicity of Buprenorphine
The apparent partition coefficients (P) obtained
using n-octanol as the organic phase exhibited the
pH dependency as predicted by the basic property of
buprenorphine with a pKa of 8.24. The obtained P values
were 2.11 ± 0.01 for pH 1.2, 25.88 ± 0.10 for pH 4.5,
2098.46 ± 109.89 for pH 6.8, and 65108.75 ± 834.01 for
pH 7.4.  However, buprenorphine was not detected in the
aqueous phase at pH 10.0.   The octanol/water partition
coefficient of buprenorphine was 1943 ± 50 in the previous literature (25).   The results indicated that buprenorphine was almost insoluble in the vehicle at pH 7.4 in this
study.   Therefore, it was suggested that the phosphate
buffer with lower pH value should be used as the vehicle
in our skin permeation studies.
II. Solubility of Buprenorphine
The solubilities of buprenorphine in phosphate
buffers at different pH were demonstrated in Table 1.
The solubility of buprenorphine in 0.1 M phosphate
buffer at pH 5.0 was thirty times higher than that at pH
7.4.  As the pH value fell, the solubility of buprenorphine
increased.  Because buprenorphine was an alkaloid with
poor water solubility, it would be protonated in low pH
phosphate buffers and this enhanced the water solubility of buprenorphine.  The intrinsic aqueous solubility of
neutral buprenorphine was 12.7 ± 1.2 μg/mL at 23°C(14).
III. Buprenorphine in Vitro Permeation Studies
(I) Influence of Vehicles at Different pH
The permeation parameters and the corresponding permeation profiles were shown in Table 1 and
Figure 1.   The relationship of pH and Jss was displayed
in Figure 2.   As expected, the pH of the vehicle in the
Franz cell highly had a impact on the penetration ability of buprenorphine.   This could be explained based
on the lipophilicity and solubility studies.   The aqueous
solubility of buprenorphine was higher at low pH (5.07.4) conditions.   We observed that higher permeability
at lower pH for buprenorphine should be attributed to
its higher solubility at lower pH, making it partition at a
faster rate from the dermal of skin into the vehicle.  The
Jss of buprenorphine increased along with the reduction
of the pH of receptor fluid. The relationship of pH and
Jss was linear (r2 = 0.9901, n =3), as shown in Figure 2.
The percentage of buprenorphine permeated was more
than 58% in the phosphate buffers at pH 5.0, 5.5, and 6.0.  
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Cumulative amount permeated (Mg/cm2)

Therefore, these pH conditions would not be appropriate to evaluate the effect of the permeation enhancers in
this study.   For this reason, the phosphate buffer at pH
6.8 would be chosen as the vehicle in the skin permeation
studies conducted.
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The objective of this study was to evaluate the
effect of various adhesive matrices on the permeation of
buprenorphine across the nude mouse skin.  Seven adhesive matrices were chosen as the transdermal drug delivery system.   The permeation parameters and the corresponding permeation profiles were shown in Table 2 and
Figure 3, respectively.   It was showed that the permeabilities of buprenorphine were higher in the PIB and SIS
adhesives than in the acrylic adhesives.   Especially, the
permeation of buprenorphine was two-fold higher in the
PIB-1 adhesive than in the Acryl-3 adhesive (see Table 2).
Same result was observed by Choi et al(18).   The permeation of ketoprofen was lower in acrylic adhesive than in
PIB adhesive, which may be due to the higher solubility of
ketoprofen in acrylic adhesive.   The better compatibility
of the functional group in the acrylic adhesive with ketoprofen reduced the permeation of ketoprofen in the acrylic
adhesive matrix.  Similar study has been observed by Choi
et al(26).  The interaction between the drug and functional
group of PSA can influence the permeation of drug. For
example, PSA containing acrylic acid (2-ethylhexylacrylate and acrylic acid copolymer, 2EHA/AA) strongly
interacted with the amide of lidocaine, and with the tertiaCumulative amount permeated (Mg/cm2)

Figure 1. Effect of phosphate buffers at different pH on the
cumulative amount of buprenorphine permeated across nude mouse
skin (mean ± SD, n = 3).
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Figure 2. The relationship of pH and Jss.
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F ig ure 3. Ef fect of a d hesives on t he cu mu lat ive a mou nt of
buprenorphine permeated across nude mouse skin (mean ± SD, n = 6).

Table 1. Solubility of buprenorphine in 0.1 M phosphate buffers at 32°C and the effect of phosphate buffers at different pH on skin permeation parameters of buprenorphine (mean ± SD, n = 3)
Vehicles (0.1 M
Phosphate buffers)

Solubility (μg/mL)

Jss (μg/cm2/h)

tL (h)

Percentage of buprenorphine
permeated (%)

pH 5.0

89.73 ± 0.15

5.80 ± 0.26

3.65 ± 1.13

87.07

pH 5.5

85.35 ± 0.06

4.87 ± 0.22

3.96 ± 1.20

70.64

pH 6.0

57.90 ± 0.03

4.00 ± 0.19

4.83 ± 1.16

58.37

pH 6.8

12.97 ± 0.03

1.62 ± 0.16

10.79 ± 1.20

19.03

pH 7.4

3.03 ± 0.01

0.82 ± 0.10

11.51 ± 1.45

10.48

12

Table 2. Effect of adhesives on skin permeation parameters of
buprenorphine (mean ± SD, n = 6)
Adhesives

Jss (µg/cm2/h)

tL (h)

Percentage of
buprenorphine
permeated (%)

PIB-1

1.57 ± 0.14

12.92 ± 1.31

18.49

PIB-2

1.52 ± 0.11

11.79 ± 1.04

17.52

SIS-1

1.49 ± 0.14

15.41 ± 0.94

16.69

Acryl-1

1.16 ± 0.13

12.66 ± 2.96

13.50

Acryl-2

1.29 ± 0.10

15.04 ± 1.45

15.48

Acryl-3

0.47 ± 0.03

11.59 ± 2.04

5.52

Acryl-4

1.12 ± 0.12

14.44 ± 1.62

12.94

Cumulative amount permeated (µg/cm2)
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Fig ure 4. Ef fect of en ha ncers on t he cu mulat ive a mou nt of
buprenorphine permeated across nude mouse skin (mean ± SD, n = 6).

ry amine of aminopyrine, The formulation of Duragesic®
(fentanyl transdermal system) contained fentanyl and alcohol which were gelled with hydroxyethyl cellulose and silicone adhesive.   No permeation enhancer was used.   The
amount of fentanyl released from each system per hour
was proportional to the surface area (2.5 μg/cm 2/h)(27).  
From the product information of Duragesic®, we observed
that the appropriate PSA used might efficiently raise the
skin permeation of drugs without using enhancers.
(III) Influence of Permeation Enhancers
In the absence of a suitable permeation enhancer, the transport of drugs across skin would be limited.
Different enhancers including lauric acid, linolenic acid,
oleic acid, menthol, glabridin, laurocapram, and NMP
were investigated to try to improve the skin permeation
of buprenorphine.   A synergistic enhancement of drug
permeation was usually accomplished by the combination
with enhancers and co-solvent PG (28). The ability of PG
to increase transdermal permeability had been attributed
to some effects. For example, the primary effect of PG
appeared to involve in a solvent-drug effect by partition-

ing into the stratum corneum itself. When PG improved
the solubility of the drugs within the stratum corneum, it
led to the enhancement of the partition of the drugs into
the skin(29). However, it was found that PG occupied the
hydrogen bonding sites of tissues, leading to decrease the
binding ability and increase lipid fluidity and permeation
of drugs(30,31). Therefore, PG was added to each formulation which contained the above enhancers.
As discussed in the influence of adhesives, it was
found that better compatibility of the functional group
in the acrylic adhesive with the drug would reduce the
permeation of the drug in the acrylic adhesive matrix.
However, the importance of the hydrogen-bonding ability
in permeation enhancers had already been observed(32).
It indicated that the possible mechanism of drug permeation enhancement by enhancers in the acrylic adhesive
might be the formation of hydrogen-bonding between the
drug and the enhancers.   It would decrease the interaction between the drug and the adhesive and then increase
the amount of drug permeated across the skin.
The permeation parameters were shown in Table 3
and the corresponding permeation profiles were shown in
Figure 4. PG/lauric acid (a saturated fatty acid, C12) and

Table 3. Effect of enhancers on skin permeation parameters of buprenorphine (mean ± SD, n = 6 )
Enhancers

Jss (µg/cm2/h)

tL (h)

ER

Percentage of buprenorphine permeated (%)

Control

1.16 ± 0.11

12.66 ± 2.96

1.00

13.50

PG/Glabridin

1.11 ± 0.09

16.17 ± 1.67

0.96

12.41

PG/Laurocapram

1.32 ± 0.08

9.07 ± 2.46

1.14

16.12

PG/NMP

1.51 ± 0.10

11.72 ± 2.02

1.30

17.76

PG/Oleic acid

1.56 ± 0.09

8.03 ± 1.45

1.34

19.31

PG/Menthol

2.10 ± 0.22

8.73 ± 3.37

1.81

25.38

PG/Linolenic acid

2.38 ± 0.15

8.46 ± 2.04

1.95

28.71

PG/Lauric acid

2.55 ± 0.18

9.16 ± 3.08

2.20

31.00
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Table 4. Effect of lauric acid or linolenic acid in different adhesives on skin permeation parameters of buprenorphine (mean ± SD, n =6 )
Jss (µg/cm2/h)

tL (h)

Percentage of buprenorphine permeated (%)

Acryl-2/PG/Lauric acid

2.68 ± 0.20

12.08 ± 1.61

31.68

Acryl-2/PG/Linolenic acid

2.34 ± 0.16

12.02 ± 1.33

27.21

SIS-1/PG/Lauric acid

2.26 ± 0.13

14.39 ± 0.69

25.59

SIS-1/PG/Linolenic acid

2.18 ± 0.18

12.25 ± 1.28

24.34

PIB-1/PG/Lauric acid

1.72 ± 0.12

11.99 ± 1.77

20.48

PIB-1/PG/Linolenic acid

1.60 ± 0.10

10.86 ± 1.67

18.70

PIB-2/PG/Lauric acid

1.62 ± 0.10

13.85 ± 1.90

18.13

PIB-2/PG/Linolenic acid

1.55 ± 0.11

11.34 ± 2.01

18.24

PG/linolenic acid (an unsaturated fatty acid with three
double bonds, C18) highly increased, while PG/oleic
acid (an unsaturated fatty acid with one double bond,
C18) slightly increased the permeation of buprenorphine compared with control test.  The highest enhancement effect in this study was achieved by PG/lauric acid.
PG/oleic acid was not potent in this study although it
was reported as an effective skin permeation enhancer
for several compounds (33,34).   The results were associated with the carbon chain length of fatty acids and the
number of double bonds.   The effect of carbon chain
length of saturated fatty acids (C7-C18) on the permeation of naloxone across human skin was studied by
Aungst. et al(35).  When the chain length increased from
C7 to C12, there was an increase in the Jss of naloxone.
However, further increase in the carbon chain length
from C12 to C18 decreased the Jss of naloxone.   It had
also been proposed that the fatty acid with 12 carbons
possessed an optimal balance between partition coefficient and affinity to skin(36).  The unsaturated fatty acids
with 18 carbons were more effective enhancers than the
corresponding saturated fatty acid in the penetration of
naloxone through human skin, as reported by Aungst. et
al(35).  As the number of double bonds increased from one
to three, Jss of naloxone increased.
The Jss of PG/lauric acid or PG/linolenic acid in our
study demonstrated that both lauric acid and linolenic
acid were effective penetration enhancers.   The longchain fatty acids in combination with PG significantly
enhanced the penetration of nicardipine and ketorolac in Rhesus Monkey(37).   The highly lipophilic basic
drug, antiestrogen, could be administered transdermally
and lauric acid or PG could increase the permeation of
it, which was observed by Lipp. et al(38). The mechanisms of the enhancing ability of fatty acids and PG
were as follows (39,40).   The mutual permeation enhancement of PG and fatty acids for drugs were firstly due to
the enhanced solubility of fatty acids and their penetration into the stratum corneum, both being caused by PG.
It was secondly due to enhanced permeability of PG,

Cumulative amount permeated (µg/cm2)
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Figure 5. Effect of lauric acid or linolenic acid in different adhesives
on the cumulative amount of buprenorphine permeated across nude
mouse skin (mean ± SD, n = 6).

which was caused by fatty acids insertion between the
intercellular lipids of the stratum corneum.   Therefore,
fatty acids acted as the “co-enhancer” and PG as the “cosolvent” in this enhancer combination(40,41).
The Jss of control test was found to be 1.16 ± 0.11 µg/
cm 2/h and the Jss of PG/glabridin was lower than that of
control test.  The Jss of PG/menthol was found to be 2.10
± 0.22 µg/cm 2/h and its ER was 1.81.  The result suggested that menthol was also a potential enhancer and could
be used in the further study.
(IV) Formulation Optimization
The permeation parameters were shown in Table 4
and the corresponding permeation profiles were shown
in Figure 5.   Comparing the Jss in Table 2 and 4, it was
shown that the enhancement of buprenorphine permeated was low in the PIB system containing PG/lauric
acid or PG/linolenic acid although the permeation of
buprenorphine was the highest in the PIB system without
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any enhancer.   However, the effect of enhancers on the
permeation of buprenorphine in the acrylic adhesive was
more remarkable than in the PIB adhesive. For example,
the Jss of buprenorphine in Acryl-2/PG/lauric acid (2.68
± 0.20 µg/cm 2/h in Table 4) was higher than in Acryl-2
only (1.29 ± 0.10 µg/cm 2/h in Table 2).  Further, the Jss of
buprenorphine in Acryl-2/PG/lauric acid was higher than
in PIB-2/PG/lauric acid (1.62 ± 0.10 µg/cm 2/h in Table 4).
Buprenorphine permeated across the nude mouse skin
in Acryl-2/PG/lauric acid was 31.68%.  The skin permeability of buprenorphine was limited because buprenorphine was a highly lipophiphic drug with high molecular
weight.  This led to the development of an acrylic adhesive combined with PG/lauric acid or PG/linolenic acid to
deliver buprenorphine across the nude mouse skin in this
study.  The fatty acids including lauric acid and linolenic
acid could indeed improve the skin penetration of some
drugs(34-40).

CONCLUSIONS
In this study, the lipophilicity, solubility, different
pH vehicles, adhesives, and permeation enhancers have
been evaluated to develop the optimal trandermal formulation for buprenorphine.   The results have indicated
that the appropriate selections of PSA and permeation
enhancers are important in the development of TDDS.
The interaction between the drug and functional group of
PSA should also be considered because it can affect the
permeation rate of a drug.  It has been demonstrated that
the permeabilities of buprenorphine are higher in the PIB
and SIS adhesive than in the acrylic adhesive.
Finally, an acrylic adhesive combined with PG
and fatty acids as enhancers have been established
to penetrate buprenorphine through the nude mouse
skin.   Among the tested enhancers, it is shown that the
enhancement effect of lauric acid and linolenic acid are
more effective than other enhancers in our study.
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